Literature DB >> 29600417

Reply to the letter to the editor: H. pylori test-and-treat should not be put off for gastric cancer prevention in East Asia any longer.

Hideki Mori1, Hidekazu Suzuki2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29600417     DOI： 10.1007/s00535-018-1454-2

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  15 in total

1.  Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.

Authors:  Hidekazu Suzuki; Toshihiro Nishizawa; Hiroe Muraoka; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

2.  Prevalence of Helicobacter pylori infection with healthy subjects in Japan.

Authors:  Yoji Hirayama; Takashi Kawai; Junji Otaki; Kohei Kawakami; Yoshimi Harada
Journal:  J Gastroenterol Hepatol       Date:  2014-12       Impact factor: 4.029

3.  Expression of CD44 and its variants on gastric epithelial cells of patients with Helicobacter pylori colonisation.

Authors:  X Fan; A Long; M Goggins; X Fan; P W Keeling; D Kelleher
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

4.  Helicobacter pylori CagA seropositivity does not influence inflammatory parameters, lipid concentrations and haemostatic factors in healthy individuals.

Authors:  F Parente; V Imbesi; C Cucino; G MacOni; U Russo; P G Duca; G Bianchi Porro
Journal:  J Intern Med       Date:  2000-02       Impact factor: 8.989

5.  Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Hitoshi Tsugawa; Seiichiro Fukuhara; Sawako Miyoshi; Kenro Hirata; Takashi Seino; Misako Matsushita; Tatsuhiro Masaoka; Takanori Kanai
Journal:  Helicobacter       Date:  2015-11-27       Impact factor: 5.753

6.  Helicobacter pylori: Helicobacter pylori gastritis--a novel distinct disease entity.

Authors:  Hidekazu Suzuki; Hideki Mori
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-09-15       Impact factor: 46.802

7.  Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2017-01-19       Impact factor: 4.623

8.  Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan.

Authors:  Momoko Tsuda; Masahiro Asaka; Mototsugu Kato; Rumiko Matsushima; Kenji Fujimori; Kozo Akino; Shogo Kikuchi; Yingsong Lin; Naoya Sakamoto
Journal:  Helicobacter       Date:  2017-08-03       Impact factor: 5.753

Review 9.  World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.

Authors:  Hidekazu Suzuki; Hideki Mori
Journal:  J Gastroenterol       Date:  2017-11-14       Impact factor: 7.527

10.  Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.

Authors:  Kazunari Murakami; Yuuichi Sakurai; Madoka Shiino; Nobuo Funao; Akira Nishimura; Masahiro Asaka
Journal:  Gut       Date:  2016-03-02       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.